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VASOCONSTRICTOR ACTIVITIES OF SOME NOVEL SYNTHETIC 
STEROIDS IN ALCOHOLIC SOLUTION 
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School of Pharmacy , Portsmouth Poly technic , Portsmouth, Rants., United Kingdom 
Ethanolic solutions of 8 new, topically active, anti-inflammatory steroids and 1 standard 
(betamethasone 17 -valerate) were assessed with a modified vascoconstrictor assay. Pallor 
was graded at 17 reading times for determination of complete blanching curves. The 
compounds were ranked by three methods: (1) summed % total possible score, (2) area under 
the blanching profile, and (3) square root transformation of sum of scores divided by number 
of volunteers, for statistical differentiation of the solutions. 
Conclusions on structure- vasoconstrictor activity relationships were that substitution or 
removal of 21 hydroxy provided compounds with a wide range of activity. Poor activity 
correlated with a hemisuccinate salt grouping at position 21 , or the absence of 11/)-hydroxy. 
The ability of topical steroids to produce skin 
blanching was first used as a method of comparison 
for these compounds by McKenzie and Stoughton 
[1 ], working with alcoholic solutions. Subsequent 
investigations [2- 5] demonstrated a relationship 
between the most effective vasoconstrictors and 
clinical usefulness as topical anti-inflammatory 
agents . The original vasoconstrictor assay was 
refined by statistical analysis of results and by the 
use of a graded scoring system [6-8]. Barry and 
Woodford [9] assessed 30 proprietary preparations 
for bioavailability employing a graded estimation 
of blanching over several reading times to provide 
information in terms of area under the blanching 
curve and summed % total possible score and also 
used this technique to assess betamethasone 17-
benzoate in gel and cream formulations [10]. This 
technique has been adapted here to assess 8 new 
steroid derivatives , synthesized on the basis of 
predicted structure- activity relationships , to-
gether with a standard, betamethasone 17 -valer-
ate. 
MATERIALS AND METHODS 
Steroids 
The novel steroids (coded in Table I) were donated by 
Organon Laboratories Ltd. The betamethasone 17 -valer-
ate was a gift from Glaxo Laboratories Ltd. Steroids 
(structural formulae in Table I) were tested as received. 
Solutions 
Pure steroids were dissolved in absolute alcohol B. P. 
to provide solutions of 10- 4 gm ml - 1, which were stored in 
coded, air-tight containers at 5° C. Thin-layer chromatog-
raphy (TLC) and ultraviolet (UV) scanning enabled com-
Manuscript received June 27 , 1974; in revised form 
January 23, 1975; accepted for publication February 3, 
1975. 
Reprint requests to: Dr. B. W. Barry, School of 
Pharmacy, Portsmouth Polytechnic, King Henry I 
Street, Portsmouth, POl 2DZ, Hants., U.K. 
parison of stabilities between freshly prepared solutions 
and samples aged for 8 months. 
TLC . Two plates, 20 x 20 em, were spread with a 
0.25-mm layer of Kieselgel G type 60 (E. Merck) and 
activated at l10°- l20°C 2 hr prior to use. Ten microliters 
of aged and fresh w-• gm ml - ' solutions of LH05 were 
applied alternately at 2-cm intervals to one plate, while 
WH14 solutions were applied to the other. The plates 
were placed in tanks saturated with toluene and ethyl 
acetate ( 1: 1). The solvent front was allowed to rise to 2 
em from the top of the plates. After drying at room tem-
perature for 5 min, the plates were sprayed with concen-
trated sulfuric acid (for LH05) or 2% v/v concentrated 
sulfuric acid in methanol (for WH14). They were then 
heated at 105• C for 5 min to develop the spots. 
UV spectrophotometry. Diluted solutions were 
scanned directly against appropriate blanks, in a 1-cm 
cell , between 200 nm and 450 nm , in an automatic 
spectrophotometer (Pye-Unicam SP800). 
Subjects 
Ten volunteers were selected from a preliminary 
screening of 14 healthy persons, without referen'ce to their 
sex or steroid sensitivity, but with reference to a consist-
ent response to a standard preparation (betamethasone 
17-valerate cream ). None had received topical steroid 
application within the previous 3 months and none were 
tested during the trials at intervals of less than 1 month. 
Methods 
Vasoconstriction was assessed in a double-blind man-
ner, solutions being applied from coded containers with 
reference to charts previously prepared from a random 
digits table ; a total of 20 sites were used for each solution. 
This minimized natural variation of vasoconstriction at 
different sites. Ten microliters ( ± 0.16 ,ul) of the steroid 
solutions and of an alcohol blank were pipetted onto the 
flexor surface of each forearm into individual , 7 -mm, 
silicone grease squares. These were stamped within 
circular punched, double adhesive-coated, Blenderm 
tape (3M Medical Products). Five milligrams of beta-
methasone 17 -valerate cream was applied to a twelfth 
site, after rejection of the first gram of product obtained 
from the tube. After evaporation, the sites were oc-
cluded for 6 hr with type S12 .urn Melinex polyester 
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TABLE I. Structural formulae of steroids 
21 CH3 20~=0 
16 
4 6 
Substituents 
Compound 
go 116 16° 17° 21 
LH02 - 0 CH 3 CH 3 OCOCHa 
LH05C - OH CH 3 CH 3 CH 3 
LH08 - OH CH 3 CH 3 OCOCH 3 
Betametha- F OH {1CH 3 ococ.Hg OH 
sone 
17-
valerate 
WH10 F OH CH 3 CH 3 OH 
WHll F OH CH 3 CH 3 OCOC2H5 
WH12 F OH CH 3 CH 3 OCOC2H.CsH5 
WH13 F OH CH 3 CH 3 OCOC 2H.COON a 
WH14 F OH CH 3 CH 3 C2H5 
a All substituents in a position, except where stated. 
bAll substituents in {1 position. 
c .1 6. 
film (ICI Plastics Division). Tapes and Melinex film were 
then removed, sites washed with soap and warm water 
(37°C) and dried gently. 
In the first trial, blanching was assessed hourly be-
tween 6 to 13 hr and every 2 hours from 24 to 32 hr. In a 
second trial, readings were taken at 16, 18, 20 and 22 hr. 
Assessment was made in constant lighting conditions and 
without reference to the application charts, using a 0-4 
scale with half-point ratings [9] as follows: 0 = normal 
skin; 1 = slight vasoconstriction; 2 = more intense vaso-
constriction with at least 2 corners outlined; 3 = gen-
eral, even vasoconstriction ; 4 = more marked vasocon-
striction with very distinct blanching. In each case, the 
first reading (6 hr) was made 10 min after removal of 
dressings so that any marginal erythema produced by this 
process had subsided and did not affect pallor assess-
ment. During trials, volunteers were asked to avoid 
elevated temperatures and contact of water with their 
arms (e.g., humid atmospheres, strenuous exercise, hot 
baths, etc.). 
RESULTS 
Solutions examined by TLC gave single spots of 
similar intensity and with reproducible Rr values. 
There was no detectable peak shift nor decrease in 
peak height observed by UV scanning. It was 
therefore assumed that negligible decomposition 
had occurred in any of the solutions during storage. 
So that results in this work could be related to 
any subsequent investigations, some method of 
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standardizing response was sought. The results 
would then take into account variable factors such 
as time of year or change in panel composition. 
Barry and Woodford [9] evolved a method for 
unification of data, a modification of which was 
employed in this work. Betamethasone 17 -valerate 
cream was applied as a standard to all volunteers." 
Summed % total possible score values were multi-
plied by the ratio: mean total values over selected 
reading times for betamethasone 17 -valerate 
cream in previous trials/summed value over same 
reading times for betamethasone 17 -valerate cream 
in this work. 
As an example: 
a. Mean of previous summed values (3 trials) for 
betametbasone 17-valerate cream over 6, 7, 8, 9, 
12, 24, and 32 hr = 383.00%. 
b. Summed value for betamethasone 17-valerate 
cream in this trial over 6, 7, 8, 9, 12, 24, and 32 hr 
= 398.75%. 
c. Thus, present % total possible score values for 
all samples are multiplied by 383.00/398.75 = 
0.9605. 
Vasoconstrictor potency was compared using 3 
parameters: (1) summed % total possible score, (2) 
area under the blanching profile, and (3) transfor-
mation of sum of scores divided by number of 
volunteers (Tm/10). 
The summed % total possible score is defined as 
the sum, over all reading times, of volunteers' total 
score expressed as % of maximum possible score. 
As an example, the maximum score per site is 4, for 
2 arms this would give 8, for 10 volunteers the total 
would be 80. In the 10-hr reading for WHll the 
score of 55 is out of a possible 80, or 68.75%. This is 
standardized (68.75% x 0.9605) to 66.03%. This 
value is summed with the other values similarly 
obtained to give the summed % total possible score 
for WHll of 432.23%. Values were similarly calcu-
lated for each steroid (Tab. II), which enabled 
ranking in order of vasoconstrictor efficacy. 
Blanching profiles were constructed by plotting 
% total possible score as ordinate against time after 
application as abscissa (Figs. 1, 2). With exception 
of WH14, the nonfluorinated steroids (LH08, 
LH05, and LH02) peaked earlier than the fluori-
nated steroids by up to 4 hr. The absolute alcohol 
placebo was at all times under 10% total possible 
score and peaked earlier than the steroids, at 7 hr. 
Betamethasone 17 -valerate cream and betametha-
sone 17-valerate solution produced strong vasocon-
striction (peak values: 78.6% and 51.0%, respec-
tively) with fairly well maintained response over 
the test period (32-hr values: 30.6% and 19.2%, 
respectively). Steroids LH08 andWH11 also· 
showed quite marked peaks (61.6% and 66.0%, 
respectively) but pallor decreased more rapidly. 
Area underneath the blanching profiles was 
obtained using a planimeter (Allbrit fixed index 
planimeter, short-arm Shandon model; W. F. 
Stanley); the areas (cm 2 ) were related to units 
equivalent to 1% total possible score for 1 hr, so 
that they could be expressed in " % total possible 
420 BARRY AND BRACE 
TABLE II. Blanchin{? responses ranked with reference to 
area under the curve values 
Blanching response 0 
Peak Area under Summed Tm/10 mean Compound time the curve % totat vatues·. square (hr) % x hr0 possible root trans-
score< formation« 
Betamethasone 11 1420 9&D B. o~ 
Y3 -"\l<a\-e1'0\cc 
cream 
WHll 10 1087 734 7.63 
WH10 11 938 607 6.88 
Betamethasone 12 901 582 6.78 
17 -valerate 
in alcohol 
LH08 9 887 613 6.92 
WH12 10 624 423 5.56 
WH14 9 573 418 5.70 
WH13 10-12 433 286 4.56 
LH05 8-9 346 256 4.47 
LH02 9 214 156 3.35 
Absolute 7 82 61.8 1.77 
alcohol 
a Values quoted to 3 significant figures. 
b Obtained by planimetry of the blanching profile. 
c The % total possible scores summed for all volunteers 
over all reading times. 
d Square root transformation of sum of scores (Tm) 
divided by number of volunteers (10). The minimum 
significant range value k = 1.45 (p < 0.05), i.e., if the 
Tm/10 values of 2 preparations differ by more than 1.45, 
there is a significant difference between those prepara-
tions. 
80 
20 
10 
WH11 
lH08 
WH14 
oL_~~_,r-~~~~~~~~~~~~s 4 
Time (tv) 
FIG. I. Vasoconstriction profiles obtained after oc-
cluded application (6 hr) of betamethasone 17 -valerate 
cream and ethanolic steroid solutions indicated. 
score x hr" units. Table II shows the steroids 
arranged in decreasing order of area under the 
curve values, enabling comparison in biologic re-
sponse-time units. It may be seen that the order is 
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not exactly the same as for summed % total 
possible score ranking. LH08 had a score of 4% 
greater than WHlO, but an area under the curve of 
51% hr less. An identical decrease in area existed 
bet:ween WH12 and WH14 but the summed% total 
possible score dropped by only 1%. 
The third classification of blanching resuits 
permitted sta.tistica.l differentiation of the sam-
pies. The summed scores of each person for each 
samp~e we:re compa1~d b)l t~~-~~ aw(»,.ly~\~ Q{ 
variance using an ICL413Q computer. The program 
provided for no transformation and 5 transforma-
tions of data-x - 1, x -~. log x, x~ and x 2 [11,12)-
with subsequent tests for non-additivity [12, 13] 
favoring the square root transformation. The 
analysis demonstrated statistically highly signifi-
cant differences between preparations (F = 42.68, 
p < 0.01) and between the volunteers (F = 6.69, 
p < 0.01). Calculation of the minimum significant 
range (k) from the Studentized range test [14] en-
abled comparison of the steroids. Significant 
differences existed when the Tm/10 values (Table 
II) differed by more than k. As an example, at the 
5% level. the nonsi~ificance values for WH11 
were 7.63 ± 1.45, (6.19-9.08). Thus WHll gave 
a significantly greater blanching response than 
steroids WH12 to LH02, inclusive, in Table II. 
Blanching due to absolute alcohol was significantly 
lower than that produced by any steroid. 
DISCUSSION 
In this work the standard McKenzie-Stoughton 
blanching test [1] has been refined by limiting 
occlusion to 6 hr and by increasing the frequency of 
observation . Similar modifications have been suc-
cessfully employed by many other workers [5, 7,9, 
10,15 ]. Placebo sites were also included in the 
tests; these received alcohol only, which produced 
some blanching. The corresponding profile (Fig. 1) 
was of similar dimensions to that observed by 
Barry and Woodford [9] for a hydrocortisone for-
mulation. This blanching may be due to increased 
hydration of the stratum corneum following occlu-
sion rather than to any direct effect of the alcohol, 
55 
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FIG. 2. Vasoconstriction profiles obtained after oc-
cluded application (6 hr) of ethanolic steroid solutions 
indicated . 
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although significant vasoconstriction to intrader-
mally injected alcohol has been noted (15 ]. 
In the assessment of relative vasoconstrictor 
potencies, consideration was given to the fact that 
individual steroids have different blanching pro-
files and a single-point reading may be taken at a 
peak, or on either an ascending or descending 
portion of each graph. 
Burdick, Haiebiian, Poulsen, and Cobner (16 I 
considered that area under the curve determina-
tions of blanching JJrofiles corresJJond to otner 
pharmacokinetic methods used to estimate 
bioavailability from oral or parenteral prepara-
tions. These authors then, however, calculated 
summed % sites exhibiting vasoconstriction (from 
information obtained at only 3 reading times) for a 
number of compounds, relative to 0.05% fluocino-
nide ointment, and correlated the results with an 
area under the curve analysis . Similarly, summed 
% total possible score has been correlated approxi-
mately with area under the curve [17] and has been 
included in this work for comparative purposes 
(Table II). A criticism of this method is that there 
are often not enough readings to accurately charac-
terize the curves; such a deficiency can cause 
reversal of a ranking order [9 ]. In this work, the 
number of readings were increased to 17 over a 
26-hr period, but a ranking reversal still occurred 
between steroids WH10 and LH08 . 
In pharmacokinetics, "true" area under the 
curve correlates with the total amount of drug 
absorbed [18] and so the areas under the blanching 
profiles were assessed after conversion into correct 
response-time units (Table II), an approach based 
on the use of integral calculus to estimate the area 
of figures bounded in part by a regular curve. This 
accounts for both of the important parameters in a 
pharmacologic response-the intensity and the 
duration of action. This method also depends on 
readings of sufficient frequency to accurately draw 
each profile. It thus follows that the error in the 
area under the curve cannot be readily assessed 
unless numerous replicate full trials are performed. 
There is also a small error in adopting an upper 
limit of 32 hr instead of reading until all signs of 
blanching have disappeared in all volunteers. 
Since Sulzberger and Witten [19] first used 
compound F (hydrocortisone) as a dermatologic 
agent, numerous modifications of the parent mole-
cule have provided steroids with increased anti-
inflammatory and low mineralocorticoid activities. 
All the steroids tested in the present study, except 
LH02, possessed the specific structural features 
which are now commonly considered desirable for 
topical activity, i.e., double bonds at C1 and C4, a 
C3 keto group, a {j-hydroxy·group at Cll, {j-methyl 
groups at C18 and C19, and a C20 keto group. 
All the novel steroids possessed an a-methyl on 
C17 instead of the more usual a-hydroxy group. 
The subsequent decrease in water solubility should 
aid penetration by providing a more favorable 
partition coefficient and by decreasing chemical 
binding within the stratum corneum or hair folli-
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cles [20 ]. Responses of the C21 alkylated steroids, 
LH05 and WH14, were low. This may be attributed 
to the hydrophilic properties being too weak to 
maintain the drugs entirely in solution throughout 
percutaneous penetration. Masking of the C21 
hydroxy group provided compounds of varying 
activity . WHlO has an unesterified C21 hydroxy 
group but was ranked below its propionate ester 
(WHll) but above its phenyl propionate ester 
(WH12). It was a considerably more effective 
vasoconstrictor tnan WH14, in which the CZl 
hydroxy had been replaced by an ethyl group. The 
weaker activities of LH05, LH02, and WH13 corre-
late respectively with absence of C9 a-fluoro and 
presence of a double bond at C6 (which would 
probably increase molecular dipole moment in the 
plane of the rings and thus decrease mobility), 
absence of the C9 a-fluoro and the Cll {j-hydroxy 
group, which has been implied as a primary 
attachment point of steroid to receptor [21] and 
strong ionic character of the C21 hemisuccinate 
salt, which would increase binding in the stratum 
corneum and reduce drug mobility. 
Approximately one-t hird of currently available 
topical steroid formulations are fluorinated , usu-
ally in the C6 and/or C9 a positions. Rein , Fleisch-
majer, and Rosenthal [22] clinically evaluated a 
new topical , fluorinated steroid-triamcinolone 
diacetate. Since then , other fluorinated com-
pounds such as fluocinolone acetonide, betametha-
sone 17 -valerate, and fluclorolone acetonide have 
proved popular, topical therapeutic agents. How-
ever, recent trends are toward the use of effective, 
nonfluorinated steroids, where possible [23- 26 ]. In 
the present work, the nonfluorinated steroid LH08 
gave a blanching response superior to 3 of the 
novel , fluorinated steroids by area under the curve 
assessment. 
Blanching results , however, should be inter-
preted with caution, as it has been found in 
comparative blanching tests with formulated oint-
ments and creams that steroids in 100% alcohol did 
not provide maximal responses (unpublished data). 
This was probably due to precipitat ion of the 
steroid [27 ]. A thin layer of crystals on t he skin 
would need redissolution , with a subsequent de-
crease in steroid penetration and vasoconstriction. 
Addition of a small percentage of nonvolatile 
solvent may well increase blanching scores. 
Selection of steroids for clinical use will involve 
considerations not dealt with in this study. The 
toxicology of the drugs requires investigation (e.g. , 
effect of overdosage, excessive effect at normal 
dosage , unwanted side effects, hypersensitivity 
reactions and idiosyncrasies, if any). An awareness 
of drug interactions, outside or within the body, 
which may have diverse effects may influence 
selection. Even though there is no irrefutable 
evidence that vasoconstriction and anti-inflamma-
tory efficacy are directly related (merely a series of 
very strong analogies), the vasoconstrictor assay is 
an extremely valuable method for rapid, preclini-
cal assessment of potential topically active ste-
422 BARR'i AND BRACE 
roids. After giving due consideration to the phys-
ico-chemical characteristics of the steroids and 
their onset of action, duration of action, and maxi-
mum intensities from alcoholic solution, the cor-
rect vehicle for each drug should be selected. Each 
formulation must be stable upon storage and the 
drug must be compatible with individual ingredi-
ents of the base, so that a low, working concentra-
tion of the drug can provide optimum bioavailabil-
ity. This implies that the steroid should possess 
maximum thermodynamic activity in the topical 
vehicle so that it is readily released from the base 
into the skin. All these factors will affect the final 
choice of a steroid to be submitted to clinical trial. 
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